nodes	percent_of_prediction	percent_of_DWPC	metapath
Canagliflozin—ALB—multiple sclerosis	0.353	1	CbGaD
Canagliflozin—ABCC2—Dexamethasone—multiple sclerosis	0.0495	0.0973	CbGbCtD
Canagliflozin—ALB—Prednisone—multiple sclerosis	0.0494	0.0971	CbGbCtD
Canagliflozin—ABCB1—Methylprednisolone—multiple sclerosis	0.0426	0.0839	CbGbCtD
Canagliflozin—ABCC2—Methotrexate—multiple sclerosis	0.0397	0.0782	CbGbCtD
Canagliflozin—CYP3A4—Fingolimod—multiple sclerosis	0.0396	0.078	CbGbCtD
Canagliflozin—ABCB1—Mitoxantrone—multiple sclerosis	0.0311	0.0612	CbGbCtD
Canagliflozin—ABCB1—Betamethasone—multiple sclerosis	0.0277	0.0545	CbGbCtD
Canagliflozin—ABCB1—Prednisolone—multiple sclerosis	0.0274	0.0538	CbGbCtD
Canagliflozin—ABCB1—Prednisone—multiple sclerosis	0.0258	0.0508	CbGbCtD
Canagliflozin—CYP3A4—Methylprednisolone—multiple sclerosis	0.0255	0.0502	CbGbCtD
Canagliflozin—ALB—Methotrexate—multiple sclerosis	0.0248	0.0487	CbGbCtD
Canagliflozin—CYP3A4—Triamcinolone—multiple sclerosis	0.0194	0.0381	CbGbCtD
Canagliflozin—CYP3A4—Mitoxantrone—multiple sclerosis	0.0186	0.0367	CbGbCtD
Canagliflozin—CYP3A4—Betamethasone—multiple sclerosis	0.0166	0.0327	CbGbCtD
Canagliflozin—CYP3A4—Prednisolone—multiple sclerosis	0.0164	0.0322	CbGbCtD
Canagliflozin—ABCB1—Dexamethasone—multiple sclerosis	0.0161	0.0317	CbGbCtD
Canagliflozin—CYP3A4—Prednisone—multiple sclerosis	0.0155	0.0304	CbGbCtD
Canagliflozin—ABCB1—Methotrexate—multiple sclerosis	0.013	0.0255	CbGbCtD
Canagliflozin—CYP3A4—Dexamethasone—multiple sclerosis	0.00966	0.019	CbGbCtD
Canagliflozin—Sunburn—Methotrexate—multiple sclerosis	0.00145	0.0161	CcSEcCtD
Canagliflozin—Serum creatinine increased—Mitoxantrone—multiple sclerosis	0.00143	0.0158	CcSEcCtD
Canagliflozin—Fracture—Methylprednisolone—multiple sclerosis	0.00114	0.0126	CcSEcCtD
Canagliflozin—Multiple fractures—Methylprednisolone—multiple sclerosis	0.00114	0.0126	CcSEcCtD
Canagliflozin—Angiopathy—Fingolimod—multiple sclerosis	0.00108	0.0119	CcSEcCtD
Canagliflozin—Renal failure acute—Cladribine—multiple sclerosis	0.00105	0.0116	CcSEcCtD
Canagliflozin—Multiple fractures—Dexamethasone—multiple sclerosis	0.00104	0.0115	CcSEcCtD
Canagliflozin—Multiple fractures—Betamethasone—multiple sclerosis	0.00104	0.0115	CcSEcCtD
Canagliflozin—Fracture—Dexamethasone—multiple sclerosis	0.00104	0.0115	CcSEcCtD
Canagliflozin—Fracture—Betamethasone—multiple sclerosis	0.00104	0.0115	CcSEcCtD
Canagliflozin—Fracture—Prednisone—multiple sclerosis	0.000904	0.00999	CcSEcCtD
Canagliflozin—Multiple fractures—Prednisone—multiple sclerosis	0.000904	0.00999	CcSEcCtD
Canagliflozin—Unspecified disorder of skin and subcutaneous tissue—Fingolimod—multiple sclerosis	0.000874	0.00966	CcSEcCtD
Canagliflozin—Hyperkalaemia—Mitoxantrone—multiple sclerosis	0.000866	0.00956	CcSEcCtD
Canagliflozin—Infection—Fingolimod—multiple sclerosis	0.000839	0.00926	CcSEcCtD
Canagliflozin—Blood urea increased—Mitoxantrone—multiple sclerosis	0.000832	0.00919	CcSEcCtD
Canagliflozin—Nervous system disorder—Fingolimod—multiple sclerosis	0.000828	0.00914	CcSEcCtD
Canagliflozin—Skin disorder—Fingolimod—multiple sclerosis	0.00082	0.00905	CcSEcCtD
Canagliflozin—Hypotension—Fingolimod—multiple sclerosis	0.000789	0.00871	CcSEcCtD
Canagliflozin—Rash erythematous—Betamethasone—multiple sclerosis	0.000788	0.0087	CcSEcCtD
Canagliflozin—Rash erythematous—Dexamethasone—multiple sclerosis	0.000788	0.0087	CcSEcCtD
Canagliflozin—Fracture—Methotrexate—multiple sclerosis	0.000756	0.00835	CcSEcCtD
Canagliflozin—Multiple fractures—Methotrexate—multiple sclerosis	0.000756	0.00835	CcSEcCtD
Canagliflozin—Urinary tract infection—Cladribine—multiple sclerosis	0.000729	0.00805	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Fingolimod—multiple sclerosis	0.000729	0.00805	CcSEcCtD
Canagliflozin—Fatigue—Fingolimod—multiple sclerosis	0.000728	0.00804	CcSEcCtD
Canagliflozin—Renal failure acute—Mitoxantrone—multiple sclerosis	0.000693	0.00765	CcSEcCtD
Canagliflozin—Pancreatitis—Azathioprine—multiple sclerosis	0.000671	0.00741	CcSEcCtD
Canagliflozin—Urinary tract disorder—Cladribine—multiple sclerosis	0.000665	0.00734	CcSEcCtD
Canagliflozin—Urethral disorder—Cladribine—multiple sclerosis	0.00066	0.00729	CcSEcCtD
Canagliflozin—Angiopathy—Cladribine—multiple sclerosis	0.000611	0.00675	CcSEcCtD
Canagliflozin—Asthenia—Fingolimod—multiple sclerosis	0.000606	0.00669	CcSEcCtD
Canagliflozin—Diabetes mellitus—Prednisolone—multiple sclerosis	0.000604	0.00666	CcSEcCtD
Canagliflozin—Blood creatinine increased—Mitoxantrone—multiple sclerosis	0.000599	0.00662	CcSEcCtD
Canagliflozin—Pruritus—Fingolimod—multiple sclerosis	0.000597	0.00659	CcSEcCtD
Canagliflozin—Dehydration—Mitoxantrone—multiple sclerosis	0.000595	0.00657	CcSEcCtD
Canagliflozin—Erythema—Cladribine—multiple sclerosis	0.000586	0.00647	CcSEcCtD
Canagliflozin—Malnutrition—Cladribine—multiple sclerosis	0.000586	0.00647	CcSEcCtD
Canagliflozin—Dizziness—Fingolimod—multiple sclerosis	0.000558	0.00616	CcSEcCtD
Canagliflozin—Diabetes mellitus—Triamcinolone—multiple sclerosis	0.000555	0.00613	CcSEcCtD
Canagliflozin—Diabetes mellitus—Methylprednisolone—multiple sclerosis	0.000554	0.00612	CcSEcCtD
Canagliflozin—Diabetes mellitus—Dexamethasone—multiple sclerosis	0.000504	0.00556	CcSEcCtD
Canagliflozin—Diabetes mellitus—Betamethasone—multiple sclerosis	0.000504	0.00556	CcSEcCtD
Canagliflozin—Unspecified disorder of skin and subcutaneous tissue—Cladribine—multiple sclerosis	0.000496	0.00547	CcSEcCtD
Canagliflozin—Urinary tract infection—Mitoxantrone—multiple sclerosis	0.000479	0.00529	CcSEcCtD
Canagliflozin—Infection—Cladribine—multiple sclerosis	0.000475	0.00525	CcSEcCtD
Canagliflozin—Nervous system disorder—Cladribine—multiple sclerosis	0.000469	0.00518	CcSEcCtD
Canagliflozin—Skin disorder—Cladribine—multiple sclerosis	0.000465	0.00513	CcSEcCtD
Canagliflozin—Hypotension—Cladribine—multiple sclerosis	0.000447	0.00494	CcSEcCtD
Canagliflozin—Pancreatitis—Prednisolone—multiple sclerosis	0.000445	0.00491	CcSEcCtD
Canagliflozin—Diabetes mellitus—Prednisone—multiple sclerosis	0.000439	0.00484	CcSEcCtD
Canagliflozin—Breast disorder—Methylprednisolone—multiple sclerosis	0.000435	0.00481	CcSEcCtD
Canagliflozin—Cystitis noninfective—Methotrexate—multiple sclerosis	0.000429	0.00474	CcSEcCtD
Canagliflozin—Cystitis—Methotrexate—multiple sclerosis	0.000424	0.00468	CcSEcCtD
Canagliflozin—Vaginal infection—Methotrexate—multiple sclerosis	0.000415	0.00458	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Cladribine—multiple sclerosis	0.000413	0.00456	CcSEcCtD
Canagliflozin—Fatigue—Cladribine—multiple sclerosis	0.000413	0.00456	CcSEcCtD
Canagliflozin—Constipation—Cladribine—multiple sclerosis	0.000409	0.00452	CcSEcCtD
Canagliflozin—Pancreatitis—Triamcinolone—multiple sclerosis	0.000409	0.00452	CcSEcCtD
Canagliflozin—Pancreatitis—Methylprednisolone—multiple sclerosis	0.000408	0.00451	CcSEcCtD
Canagliflozin—Unspecified disorder of skin and subcutaneous tissue—Azathioprine—multiple sclerosis	0.000403	0.00445	CcSEcCtD
Canagliflozin—Urine output increased—Methotrexate—multiple sclerosis	0.000397	0.00438	CcSEcCtD
Canagliflozin—Bladder pain—Methotrexate—multiple sclerosis	0.000397	0.00438	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Cladribine—multiple sclerosis	0.000391	0.00432	CcSEcCtD
Canagliflozin—Infection—Azathioprine—multiple sclerosis	0.000387	0.00427	CcSEcCtD
Canagliflozin—Erythema—Mitoxantrone—multiple sclerosis	0.000385	0.00426	CcSEcCtD
Canagliflozin—Urticaria—Cladribine—multiple sclerosis	0.00038	0.0042	CcSEcCtD
Canagliflozin—Abdominal pain—Cladribine—multiple sclerosis	0.000378	0.00418	CcSEcCtD
Canagliflozin—Skin disorder—Azathioprine—multiple sclerosis	0.000378	0.00417	CcSEcCtD
Canagliflozin—Diabetes mellitus—Methotrexate—multiple sclerosis	0.000367	0.00405	CcSEcCtD
Canagliflozin—Hypotension—Azathioprine—multiple sclerosis	0.000364	0.00401	CcSEcCtD
Canagliflozin—Photosensitivity—Methotrexate—multiple sclerosis	0.000363	0.00401	CcSEcCtD
Canagliflozin—Polyuria—Methotrexate—multiple sclerosis	0.000363	0.00401	CcSEcCtD
Canagliflozin—Hypersensitivity—Cladribine—multiple sclerosis	0.000353	0.00389	CcSEcCtD
Canagliflozin—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP27B1—multiple sclerosis	0.00035	0.00729	CbGpPWpGaD
Canagliflozin—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP24A1—multiple sclerosis	0.00035	0.00729	CbGpPWpGaD
Canagliflozin—Renal failure acute—Methotrexate—multiple sclerosis	0.000345	0.00381	CcSEcCtD
Canagliflozin—Asthenia—Cladribine—multiple sclerosis	0.000343	0.00379	CcSEcCtD
Canagliflozin—Pruritus—Cladribine—multiple sclerosis	0.000339	0.00374	CcSEcCtD
Canagliflozin—UGT1A9—Biological oxidations—CYP24A1—multiple sclerosis	0.000338	0.00705	CbGpPWpGaD
Canagliflozin—UGT1A9—Biological oxidations—CYP27B1—multiple sclerosis	0.000338	0.00705	CbGpPWpGaD
Canagliflozin—Gastrointestinal disorder—Azathioprine—multiple sclerosis	0.000336	0.00371	CcSEcCtD
Canagliflozin—Convulsion—Mitoxantrone—multiple sclerosis	0.000334	0.00369	CcSEcCtD
Canagliflozin—UGT1A9—Metapathway biotransformation—CYP24A1—multiple sclerosis	0.000334	0.00695	CbGpPWpGaD
Canagliflozin—UGT1A9—Metapathway biotransformation—CYP27B1—multiple sclerosis	0.000334	0.00695	CbGpPWpGaD
Canagliflozin—ALB—HDL-mediated lipid transport—APOE—multiple sclerosis	0.000327	0.0068	CbGpPWpGaD
Canagliflozin—ABCB1—Drug Induction of Bile Acid Pathway—VDR—multiple sclerosis	0.000323	0.00674	CbGpPWpGaD
Canagliflozin—Pancreatitis—Prednisone—multiple sclerosis	0.000323	0.00357	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Azathioprine—multiple sclerosis	0.000318	0.00351	CcSEcCtD
Canagliflozin—Dizziness—Cladribine—multiple sclerosis	0.000316	0.00349	CcSEcCtD
Canagliflozin—Erythema—Prednisolone—multiple sclerosis	0.000316	0.00349	CcSEcCtD
Canagliflozin—Infection—Mitoxantrone—multiple sclerosis	0.000312	0.00345	CcSEcCtD
Canagliflozin—CYP3A4—Irinotecan Pathway—BCHE—multiple sclerosis	0.00031	0.00645	CbGpPWpGaD
Canagliflozin—Shock—Mitoxantrone—multiple sclerosis	0.000309	0.00342	CcSEcCtD
Canagliflozin—Abdominal pain—Azathioprine—multiple sclerosis	0.000308	0.0034	CcSEcCtD
Canagliflozin—Skin disorder—Mitoxantrone—multiple sclerosis	0.000305	0.00337	CcSEcCtD
Canagliflozin—Angiopathy—Methylprednisolone—multiple sclerosis	0.000302	0.00334	CcSEcCtD
Canagliflozin—Rash—Cladribine—multiple sclerosis	0.000302	0.00333	CcSEcCtD
Canagliflozin—Dermatitis—Cladribine—multiple sclerosis	0.000301	0.00333	CcSEcCtD
Canagliflozin—Hypotension—Mitoxantrone—multiple sclerosis	0.000294	0.00325	CcSEcCtD
Canagliflozin—Erythema—Triamcinolone—multiple sclerosis	0.000291	0.00321	CcSEcCtD
Canagliflozin—Erythema—Methylprednisolone—multiple sclerosis	0.00029	0.0032	CcSEcCtD
Canagliflozin—Malnutrition—Methylprednisolone—multiple sclerosis	0.00029	0.0032	CcSEcCtD
Canagliflozin—Angioedema—Prednisolone—multiple sclerosis	0.000289	0.00319	CcSEcCtD
Canagliflozin—Breast disorder—Methotrexate—multiple sclerosis	0.000288	0.00318	CcSEcCtD
Canagliflozin—SLC5A2—Metabolism—SRM—multiple sclerosis	0.000287	0.00599	CbGpPWpGaD
Canagliflozin—SLC5A1—Metabolism—SRM—multiple sclerosis	0.000287	0.00599	CbGpPWpGaD
Canagliflozin—Hypersensitivity—Azathioprine—multiple sclerosis	0.000287	0.00317	CcSEcCtD
Canagliflozin—Nausea—Cladribine—multiple sclerosis	0.000284	0.00314	CcSEcCtD
Canagliflozin—Syncope—Prednisolone—multiple sclerosis	0.000284	0.00313	CcSEcCtD
Canagliflozin—SLC5A2—Transmembrane transport of small molecules—AQP4—multiple sclerosis	0.000279	0.00581	CbGpPWpGaD
Canagliflozin—SLC5A1—Transmembrane transport of small molecules—AQP4—multiple sclerosis	0.000279	0.00581	CbGpPWpGaD
Canagliflozin—Loss of consciousness—Prednisolone—multiple sclerosis	0.000278	0.00307	CcSEcCtD
Canagliflozin—Angiopathy—Betamethasone—multiple sclerosis	0.000275	0.00304	CcSEcCtD
Canagliflozin—Angiopathy—Dexamethasone—multiple sclerosis	0.000275	0.00304	CcSEcCtD
Canagliflozin—Convulsion—Prednisolone—multiple sclerosis	0.000274	0.00302	CcSEcCtD
Canagliflozin—Fatigue—Mitoxantrone—multiple sclerosis	0.000271	0.00299	CcSEcCtD
Canagliflozin—Pancreatitis—Methotrexate—multiple sclerosis	0.00027	0.00298	CcSEcCtD
Canagliflozin—Constipation—Mitoxantrone—multiple sclerosis	0.000269	0.00297	CcSEcCtD
Canagliflozin—ALB—Platelet degranulation—PLEK—multiple sclerosis	0.000266	0.00555	CbGpPWpGaD
Canagliflozin—Angioedema—Triamcinolone—multiple sclerosis	0.000266	0.00293	CcSEcCtD
Canagliflozin—Angioedema—Methylprednisolone—multiple sclerosis	0.000265	0.00293	CcSEcCtD
Canagliflozin—Erythema—Dexamethasone—multiple sclerosis	0.000264	0.00291	CcSEcCtD
Canagliflozin—Erythema—Betamethasone—multiple sclerosis	0.000264	0.00291	CcSEcCtD
Canagliflozin—Syncope—Triamcinolone—multiple sclerosis	0.000261	0.00288	CcSEcCtD
Canagliflozin—Syncope—Methylprednisolone—multiple sclerosis	0.00026	0.00287	CcSEcCtD
Canagliflozin—Dizziness—Azathioprine—multiple sclerosis	0.000257	0.00284	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Mitoxantrone—multiple sclerosis	0.000257	0.00284	CcSEcCtD
Canagliflozin—Loss of consciousness—Triamcinolone—multiple sclerosis	0.000256	0.00282	CcSEcCtD
Canagliflozin—Loss of consciousness—Methylprednisolone—multiple sclerosis	0.000255	0.00282	CcSEcCtD
Canagliflozin—Shock—Prednisolone—multiple sclerosis	0.000254	0.0028	CcSEcCtD
Canagliflozin—ALB—Response to elevated platelet cytosolic Ca2+—PLEK—multiple sclerosis	0.000254	0.00529	CbGpPWpGaD
Canagliflozin—Convulsion—Triamcinolone—multiple sclerosis	0.000252	0.00278	CcSEcCtD
Canagliflozin—Photosensitivity reaction—Methotrexate—multiple sclerosis	0.000252	0.00278	CcSEcCtD
Canagliflozin—Convulsion—Methylprednisolone—multiple sclerosis	0.000251	0.00278	CcSEcCtD
Canagliflozin—Urticaria—Mitoxantrone—multiple sclerosis	0.00025	0.00276	CcSEcCtD
Canagliflozin—Abdominal pain—Mitoxantrone—multiple sclerosis	0.000249	0.00275	CcSEcCtD
Canagliflozin—SLC5A1—Transmembrane transport of small molecules—SLC11A1—multiple sclerosis	0.000246	0.00513	CbGpPWpGaD
Canagliflozin—SLC5A2—Transmembrane transport of small molecules—SLC11A1—multiple sclerosis	0.000246	0.00513	CbGpPWpGaD
Canagliflozin—ABCB1—Allograft Rejection—C4A—multiple sclerosis	0.000246	0.00512	CbGpPWpGaD
Canagliflozin—Rash—Azathioprine—multiple sclerosis	0.000245	0.00271	CcSEcCtD
Canagliflozin—Unspecified disorder of skin and subcutaneous tissue—Methylprednisolone—multiple sclerosis	0.000245	0.00271	CcSEcCtD
Canagliflozin—Dermatitis—Azathioprine—multiple sclerosis	0.000245	0.00271	CcSEcCtD
Canagliflozin—Dry mouth—Triamcinolone—multiple sclerosis	0.000242	0.00267	CcSEcCtD
Canagliflozin—Angioedema—Dexamethasone—multiple sclerosis	0.000241	0.00266	CcSEcCtD
Canagliflozin—Angioedema—Betamethasone—multiple sclerosis	0.000241	0.00266	CcSEcCtD
Canagliflozin—Angiopathy—Prednisone—multiple sclerosis	0.000239	0.00264	CcSEcCtD
Canagliflozin—Syncope—Betamethasone—multiple sclerosis	0.000237	0.00261	CcSEcCtD
Canagliflozin—Syncope—Dexamethasone—multiple sclerosis	0.000237	0.00261	CcSEcCtD
Canagliflozin—Infection—Triamcinolone—multiple sclerosis	0.000236	0.0026	CcSEcCtD
Canagliflozin—Infection—Methylprednisolone—multiple sclerosis	0.000235	0.0026	CcSEcCtD
Canagliflozin—Shock—Triamcinolone—multiple sclerosis	0.000233	0.00258	CcSEcCtD
Canagliflozin—Shock—Methylprednisolone—multiple sclerosis	0.000233	0.00257	CcSEcCtD
Canagliflozin—Nervous system disorder—Methylprednisolone—multiple sclerosis	0.000232	0.00256	CcSEcCtD
Canagliflozin—Loss of consciousness—Betamethasone—multiple sclerosis	0.000232	0.00256	CcSEcCtD
Canagliflozin—Loss of consciousness—Dexamethasone—multiple sclerosis	0.000232	0.00256	CcSEcCtD
Canagliflozin—Hypersensitivity—Mitoxantrone—multiple sclerosis	0.000232	0.00256	CcSEcCtD
Canagliflozin—Nausea—Azathioprine—multiple sclerosis	0.000231	0.00255	CcSEcCtD
Canagliflozin—Skin disorder—Methylprednisolone—multiple sclerosis	0.00023	0.00254	CcSEcCtD
Canagliflozin—Erythema—Prednisone—multiple sclerosis	0.00023	0.00254	CcSEcCtD
Canagliflozin—Malnutrition—Prednisone—multiple sclerosis	0.00023	0.00254	CcSEcCtD
Canagliflozin—Convulsion—Dexamethasone—multiple sclerosis	0.000229	0.00252	CcSEcCtD
Canagliflozin—Convulsion—Betamethasone—multiple sclerosis	0.000229	0.00252	CcSEcCtD
Canagliflozin—Asthenia—Mitoxantrone—multiple sclerosis	0.000226	0.00249	CcSEcCtD
Canagliflozin—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP24A1—multiple sclerosis	0.000222	0.00463	CbGpPWpGaD
Canagliflozin—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP27B1—multiple sclerosis	0.000222	0.00463	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—SRM—multiple sclerosis	0.000222	0.00462	CbGpPWpGaD
Canagliflozin—Hypotension—Methylprednisolone—multiple sclerosis	0.000221	0.00244	CcSEcCtD
Canagliflozin—SLC5A2—Disease—GPC5—multiple sclerosis	0.000221	0.00461	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—GPC5—multiple sclerosis	0.000221	0.00461	CbGpPWpGaD
Canagliflozin—CYP3A4—Oxidation by Cytochrome P450—CYP24A1—multiple sclerosis	0.000219	0.00457	CbGpPWpGaD
Canagliflozin—CYP3A4—Oxidation by Cytochrome P450—CYP27B1—multiple sclerosis	0.000219	0.00457	CbGpPWpGaD
Canagliflozin—Urinary tract disorder—Methotrexate—multiple sclerosis	0.000218	0.00241	CcSEcCtD
Canagliflozin—Urethral disorder—Methotrexate—multiple sclerosis	0.000216	0.00239	CcSEcCtD
Canagliflozin—Infection—Dexamethasone—multiple sclerosis	0.000214	0.00236	CcSEcCtD
Canagliflozin—Infection—Betamethasone—multiple sclerosis	0.000214	0.00236	CcSEcCtD
Canagliflozin—Shock—Betamethasone—multiple sclerosis	0.000212	0.00234	CcSEcCtD
Canagliflozin—Shock—Dexamethasone—multiple sclerosis	0.000212	0.00234	CcSEcCtD
Canagliflozin—Nervous system disorder—Betamethasone—multiple sclerosis	0.000211	0.00233	CcSEcCtD
Canagliflozin—Nervous system disorder—Dexamethasone—multiple sclerosis	0.000211	0.00233	CcSEcCtD
Canagliflozin—Angioedema—Prednisone—multiple sclerosis	0.00021	0.00232	CcSEcCtD
Canagliflozin—Syncope—Prednisone—multiple sclerosis	0.000206	0.00228	CcSEcCtD
Canagliflozin—UGT2B4—Biological oxidations—POMC—multiple sclerosis	0.000206	0.00429	CbGpPWpGaD
Canagliflozin—Urticaria—Prednisolone—multiple sclerosis	0.000205	0.00226	CcSEcCtD
Canagliflozin—Fatigue—Triamcinolone—multiple sclerosis	0.000205	0.00226	CcSEcCtD
Canagliflozin—Fatigue—Methylprednisolone—multiple sclerosis	0.000204	0.00225	CcSEcCtD
Canagliflozin—SLC5A2—Metabolism—CYP24A1—multiple sclerosis	0.000203	0.00422	CbGpPWpGaD
Canagliflozin—SLC5A2—Metabolism—CYP27B1—multiple sclerosis	0.000203	0.00422	CbGpPWpGaD
Canagliflozin—SLC5A1—Metabolism—CYP24A1—multiple sclerosis	0.000203	0.00422	CbGpPWpGaD
Canagliflozin—SLC5A1—Metabolism—CYP27B1—multiple sclerosis	0.000203	0.00422	CbGpPWpGaD
Canagliflozin—Loss of consciousness—Prednisone—multiple sclerosis	0.000202	0.00223	CcSEcCtD
Canagliflozin—Hypotension—Dexamethasone—multiple sclerosis	0.000201	0.00222	CcSEcCtD
Canagliflozin—Hypotension—Betamethasone—multiple sclerosis	0.000201	0.00222	CcSEcCtD
Canagliflozin—ABCB1—Allograft Rejection—CXCL13—multiple sclerosis	0.000201	0.00418	CbGpPWpGaD
Canagliflozin—ABCB1—Allograft Rejection—IL12A—multiple sclerosis	0.000201	0.00418	CbGpPWpGaD
Canagliflozin—Angiopathy—Methotrexate—multiple sclerosis	0.0002	0.00221	CcSEcCtD
Canagliflozin—UGT1A9—PPAR Alpha Pathway—MYC—multiple sclerosis	0.000199	0.00416	CbGpPWpGaD
Canagliflozin—CYP3A4—Drug Induction of Bile Acid Pathway—VDR—multiple sclerosis	0.000199	0.00415	CbGpPWpGaD
Canagliflozin—Convulsion—Prednisone—multiple sclerosis	0.000199	0.0022	CcSEcCtD
Canagliflozin—Rash—Mitoxantrone—multiple sclerosis	0.000198	0.00219	CcSEcCtD
Canagliflozin—Dermatitis—Mitoxantrone—multiple sclerosis	0.000198	0.00219	CcSEcCtD
Canagliflozin—Unspecified disorder of skin and subcutaneous tissue—Prednisone—multiple sclerosis	0.000194	0.00214	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Methylprednisolone—multiple sclerosis	0.000194	0.00214	CcSEcCtD
Canagliflozin—Malnutrition—Methotrexate—multiple sclerosis	0.000192	0.00212	CcSEcCtD
Canagliflozin—Erythema—Methotrexate—multiple sclerosis	0.000192	0.00212	CcSEcCtD
Canagliflozin—Hypersensitivity—Prednisolone—multiple sclerosis	0.00019	0.0021	CcSEcCtD
Canagliflozin—Urticaria—Triamcinolone—multiple sclerosis	0.000189	0.00208	CcSEcCtD
Canagliflozin—Urticaria—Methylprednisolone—multiple sclerosis	0.000188	0.00208	CcSEcCtD
Canagliflozin—ALB—Lipoprotein metabolism—APOE—multiple sclerosis	0.000188	0.00391	CbGpPWpGaD
Canagliflozin—Abdominal pain—Methylprednisolone—multiple sclerosis	0.000187	0.00207	CcSEcCtD
Canagliflozin—Nausea—Mitoxantrone—multiple sclerosis	0.000187	0.00206	CcSEcCtD
Canagliflozin—Infection—Prednisone—multiple sclerosis	0.000186	0.00206	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Betamethasone—multiple sclerosis	0.000186	0.00205	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Dexamethasone—multiple sclerosis	0.000186	0.00205	CcSEcCtD
Canagliflozin—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—multiple sclerosis	0.000186	0.00387	CbGpPWpGaD
Canagliflozin—Fatigue—Dexamethasone—multiple sclerosis	0.000186	0.00205	CcSEcCtD
Canagliflozin—Fatigue—Betamethasone—multiple sclerosis	0.000186	0.00205	CcSEcCtD
Canagliflozin—SLC5A2—Metabolism—GPC5—multiple sclerosis	0.000185	0.00386	CbGpPWpGaD
Canagliflozin—SLC5A1—Metabolism—GPC5—multiple sclerosis	0.000185	0.00386	CbGpPWpGaD
Canagliflozin—Shock—Prednisone—multiple sclerosis	0.000184	0.00204	CcSEcCtD
Canagliflozin—Nervous system disorder—Prednisone—multiple sclerosis	0.000184	0.00203	CcSEcCtD
Canagliflozin—ABCB1—Allograft Rejection—HLA-DRA—multiple sclerosis	0.000182	0.0038	CbGpPWpGaD
Canagliflozin—Skin disorder—Prednisone—multiple sclerosis	0.000182	0.00201	CcSEcCtD
Canagliflozin—UGT1A9—Aryl Hydrocarbon Receptor Pathway—IFNG—multiple sclerosis	0.000182	0.00379	CbGpPWpGaD
Canagliflozin—CYP3A4—Phase 1 - Functionalization of compounds—CYP27B1—multiple sclerosis	0.00018	0.00375	CbGpPWpGaD
Canagliflozin—CYP3A4—Phase 1 - Functionalization of compounds—CYP24A1—multiple sclerosis	0.00018	0.00375	CbGpPWpGaD
Canagliflozin—Gastrointestinal pain—Betamethasone—multiple sclerosis	0.000176	0.00194	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Dexamethasone—multiple sclerosis	0.000176	0.00194	CcSEcCtD
Canagliflozin—SLC5A1—NRF2 pathway—TGFB1—multiple sclerosis	0.000175	0.00365	CbGpPWpGaD
Canagliflozin—SLC5A2—NRF2 pathway—TGFB1—multiple sclerosis	0.000175	0.00365	CbGpPWpGaD
Canagliflozin—Hypersensitivity—Triamcinolone—multiple sclerosis	0.000175	0.00193	CcSEcCtD
Canagliflozin—SLC5A2—SLC-mediated transmembrane transport—ALB—multiple sclerosis	0.000175	0.00364	CbGpPWpGaD
Canagliflozin—SLC5A1—SLC-mediated transmembrane transport—ALB—multiple sclerosis	0.000175	0.00364	CbGpPWpGaD
Canagliflozin—Hypersensitivity—Methylprednisolone—multiple sclerosis	0.000174	0.00193	CcSEcCtD
Canagliflozin—ABCB1—Allograft Rejection—FOXP3—multiple sclerosis	0.000172	0.00358	CbGpPWpGaD
Canagliflozin—Urticaria—Dexamethasone—multiple sclerosis	0.000171	0.00189	CcSEcCtD
Canagliflozin—Urticaria—Betamethasone—multiple sclerosis	0.000171	0.00189	CcSEcCtD
Canagliflozin—Dizziness—Prednisolone—multiple sclerosis	0.000171	0.00188	CcSEcCtD
Canagliflozin—Asthenia—Triamcinolone—multiple sclerosis	0.00017	0.00188	CcSEcCtD
Canagliflozin—Abdominal pain—Betamethasone—multiple sclerosis	0.00017	0.00188	CcSEcCtD
Canagliflozin—Abdominal pain—Dexamethasone—multiple sclerosis	0.00017	0.00188	CcSEcCtD
Canagliflozin—Asthenia—Methylprednisolone—multiple sclerosis	0.00017	0.00188	CcSEcCtD
Canagliflozin—Pruritus—Triamcinolone—multiple sclerosis	0.000168	0.00185	CcSEcCtD
Canagliflozin—Pruritus—Methylprednisolone—multiple sclerosis	0.000168	0.00185	CcSEcCtD
Canagliflozin—Convulsion—Methotrexate—multiple sclerosis	0.000166	0.00184	CcSEcCtD
Canagliflozin—Rash—Prednisolone—multiple sclerosis	0.000163	0.0018	CcSEcCtD
Canagliflozin—Dermatitis—Prednisolone—multiple sclerosis	0.000163	0.00179	CcSEcCtD
Canagliflozin—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—multiple sclerosis	0.000162	0.00179	CcSEcCtD
Canagliflozin—UGT1A9—Aryl Hydrocarbon Receptor Pathway—IL1B—multiple sclerosis	0.000162	0.00338	CbGpPWpGaD
Canagliflozin—Fatigue—Prednisone—multiple sclerosis	0.000162	0.00179	CcSEcCtD
Canagliflozin—UGT1A9—Aryl Hydrocarbon Receptor Pathway—IL2—multiple sclerosis	0.000162	0.00337	CbGpPWpGaD
Canagliflozin—Constipation—Prednisone—multiple sclerosis	0.00016	0.00177	CcSEcCtD
Canagliflozin—Dizziness—Triamcinolone—multiple sclerosis	0.000157	0.00173	CcSEcCtD
Canagliflozin—Dizziness—Methylprednisolone—multiple sclerosis	0.000157	0.00173	CcSEcCtD
Canagliflozin—UGT2B4—Metabolism—CYP27B1—multiple sclerosis	0.000156	0.00326	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—CYP24A1—multiple sclerosis	0.000156	0.00326	CbGpPWpGaD
Canagliflozin—ABCB1—Allograft Rejection—HLA-G—multiple sclerosis	0.000156	0.00325	CbGpPWpGaD
Canagliflozin—Infection—Methotrexate—multiple sclerosis	0.000156	0.00172	CcSEcCtD
Canagliflozin—Asthenia—Betamethasone—multiple sclerosis	0.000154	0.00171	CcSEcCtD
Canagliflozin—Asthenia—Dexamethasone—multiple sclerosis	0.000154	0.00171	CcSEcCtD
Canagliflozin—Nervous system disorder—Methotrexate—multiple sclerosis	0.000154	0.0017	CcSEcCtD
Canagliflozin—SLC5A1—Metabolism—RRM1—multiple sclerosis	0.000153	0.0032	CbGpPWpGaD
Canagliflozin—SLC5A2—Metabolism—RRM1—multiple sclerosis	0.000153	0.0032	CbGpPWpGaD
Canagliflozin—Gastrointestinal pain—Prednisone—multiple sclerosis	0.000153	0.00169	CcSEcCtD
Canagliflozin—Nausea—Prednisolone—multiple sclerosis	0.000153	0.00169	CcSEcCtD
Canagliflozin—Pruritus—Betamethasone—multiple sclerosis	0.000152	0.00168	CcSEcCtD
Canagliflozin—Pruritus—Dexamethasone—multiple sclerosis	0.000152	0.00168	CcSEcCtD
Canagliflozin—Skin disorder—Methotrexate—multiple sclerosis	0.000152	0.00168	CcSEcCtD
Canagliflozin—ALB—Vitamin B12 Metabolism—CCL5—multiple sclerosis	0.00015	0.00312	CbGpPWpGaD
Canagliflozin—Rash—Triamcinolone—multiple sclerosis	0.00015	0.00165	CcSEcCtD
Canagliflozin—Dermatitis—Triamcinolone—multiple sclerosis	0.000149	0.00165	CcSEcCtD
Canagliflozin—Rash—Methylprednisolone—multiple sclerosis	0.000149	0.00165	CcSEcCtD
Canagliflozin—Dermatitis—Methylprednisolone—multiple sclerosis	0.000149	0.00165	CcSEcCtD
Canagliflozin—Urticaria—Prednisone—multiple sclerosis	0.000149	0.00164	CcSEcCtD
Canagliflozin—Abdominal pain—Prednisone—multiple sclerosis	0.000148	0.00164	CcSEcCtD
Canagliflozin—Hypotension—Methotrexate—multiple sclerosis	0.000146	0.00162	CcSEcCtD
Canagliflozin—ALB—Binding and Uptake of Ligands by Scavenger Receptors—APOE—multiple sclerosis	0.000146	0.00304	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—RPL5—multiple sclerosis	0.000144	0.003	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—RPL5—multiple sclerosis	0.000144	0.003	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—GPC5—multiple sclerosis	0.000143	0.00298	CbGpPWpGaD
Canagliflozin—Dizziness—Dexamethasone—multiple sclerosis	0.000142	0.00157	CcSEcCtD
Canagliflozin—Dizziness—Betamethasone—multiple sclerosis	0.000142	0.00157	CcSEcCtD
Canagliflozin—Nausea—Triamcinolone—multiple sclerosis	0.000141	0.00156	CcSEcCtD
Canagliflozin—Nausea—Methylprednisolone—multiple sclerosis	0.000141	0.00155	CcSEcCtD
Canagliflozin—Hypersensitivity—Prednisone—multiple sclerosis	0.000138	0.00153	CcSEcCtD
Canagliflozin—SLC5A1—Disease—SLC11A1—multiple sclerosis	0.000138	0.00287	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—SLC11A1—multiple sclerosis	0.000138	0.00287	CbGpPWpGaD
Canagliflozin—ALB—SLC-mediated transmembrane transport—SLC15A2—multiple sclerosis	0.000137	0.00285	CbGpPWpGaD
Canagliflozin—Rash—Dexamethasone—multiple sclerosis	0.000136	0.0015	CcSEcCtD
Canagliflozin—Rash—Betamethasone—multiple sclerosis	0.000136	0.0015	CcSEcCtD
Canagliflozin—Dermatitis—Dexamethasone—multiple sclerosis	0.000136	0.0015	CcSEcCtD
Canagliflozin—Dermatitis—Betamethasone—multiple sclerosis	0.000136	0.0015	CcSEcCtD
Canagliflozin—ABCB1—Allograft Rejection—IL17A—multiple sclerosis	0.000135	0.00282	CbGpPWpGaD
Canagliflozin—Gastrointestinal disorder—Methotrexate—multiple sclerosis	0.000135	0.00149	CcSEcCtD
Canagliflozin—Fatigue—Methotrexate—multiple sclerosis	0.000135	0.00149	CcSEcCtD
Canagliflozin—Asthenia—Prednisone—multiple sclerosis	0.000135	0.00149	CcSEcCtD
Canagliflozin—Pruritus—Prednisone—multiple sclerosis	0.000133	0.00146	CcSEcCtD
Canagliflozin—ABCB1—Allograft Rejection—CD28—multiple sclerosis	0.000132	0.00274	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—CYP27B1—multiple sclerosis	0.00013	0.00271	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—CYP24A1—multiple sclerosis	0.00013	0.00271	CbGpPWpGaD
Canagliflozin—ABCC2—Transmembrane transport of small molecules—SLC15A2—multiple sclerosis	0.00013	0.0027	CbGpPWpGaD
Canagliflozin—Gastrointestinal pain—Methotrexate—multiple sclerosis	0.000128	0.00141	CcSEcCtD
Canagliflozin—Nausea—Betamethasone—multiple sclerosis	0.000128	0.00141	CcSEcCtD
Canagliflozin—Nausea—Dexamethasone—multiple sclerosis	0.000128	0.00141	CcSEcCtD
Canagliflozin—UGT1A9—Aryl Hydrocarbon Receptor Pathway—TGFB1—multiple sclerosis	0.000126	0.00263	CbGpPWpGaD
Canagliflozin—ABCB1—Allograft Rejection—IL12B—multiple sclerosis	0.000126	0.00262	CbGpPWpGaD
Canagliflozin—ABCB1—Allograft Rejection—HLA-DPB1—multiple sclerosis	0.000125	0.0026	CbGpPWpGaD
Canagliflozin—ALB—Lipid and lipoprotein metabolism—APOE—multiple sclerosis	0.000125	0.0026	CbGpPWpGaD
Canagliflozin—Urticaria—Methotrexate—multiple sclerosis	0.000124	0.00137	CcSEcCtD
Canagliflozin—Dizziness—Prednisone—multiple sclerosis	0.000124	0.00137	CcSEcCtD
Canagliflozin—Abdominal pain—Methotrexate—multiple sclerosis	0.000124	0.00137	CcSEcCtD
Canagliflozin—ALB—Vitamin B12 Metabolism—APOE—multiple sclerosis	0.000123	0.00256	CbGpPWpGaD
Canagliflozin—ABCB1—Allograft Rejection—CD40—multiple sclerosis	0.00012	0.0025	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—RRM1—multiple sclerosis	0.000118	0.00247	CbGpPWpGaD
Canagliflozin—ABCB1—Allograft Rejection—CTLA4—multiple sclerosis	0.000118	0.00247	CbGpPWpGaD
Canagliflozin—Rash—Prednisone—multiple sclerosis	0.000118	0.00131	CcSEcCtD
Canagliflozin—ALB—Platelet activation, signaling and aggregation—PLEK—multiple sclerosis	0.000118	0.00246	CbGpPWpGaD
Canagliflozin—Dermatitis—Prednisone—multiple sclerosis	0.000118	0.0013	CcSEcCtD
Canagliflozin—ALB—Folate Metabolism—IL4—multiple sclerosis	0.000118	0.00246	CbGpPWpGaD
Canagliflozin—UGT1A9—Aryl Hydrocarbon Receptor Pathway—TNF—multiple sclerosis	0.000118	0.00245	CbGpPWpGaD
Canagliflozin—Hypersensitivity—Methotrexate—multiple sclerosis	0.000115	0.00127	CcSEcCtD
Canagliflozin—ALB—Vitamin B12 Metabolism—ICAM1—multiple sclerosis	0.000115	0.0024	CbGpPWpGaD
Canagliflozin—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—multiple sclerosis	0.000114	0.00238	CbGpPWpGaD
Canagliflozin—Asthenia—Methotrexate—multiple sclerosis	0.000112	0.00124	CcSEcCtD
Canagliflozin—Nausea—Prednisone—multiple sclerosis	0.000111	0.00123	CcSEcCtD
Canagliflozin—Pruritus—Methotrexate—multiple sclerosis	0.000111	0.00122	CcSEcCtD
Canagliflozin—SLC5A2—Disease—CD28—multiple sclerosis	0.00011	0.00229	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—CD28—multiple sclerosis	0.00011	0.00229	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—RRM1—multiple sclerosis	0.000108	0.00225	CbGpPWpGaD
Canagliflozin—ABCB1—Allograft Rejection—HLA-DQA1—multiple sclerosis	0.000104	0.00217	CbGpPWpGaD
Canagliflozin—ALB—SLC-mediated transmembrane transport—SLC30A7—multiple sclerosis	0.000104	0.00216	CbGpPWpGaD
Canagliflozin—Dizziness—Methotrexate—multiple sclerosis	0.000104	0.00114	CcSEcCtD
Canagliflozin—ALB—Vitamin B12 Metabolism—CCL2—multiple sclerosis	0.000103	0.00215	CbGpPWpGaD
Canagliflozin—Rash—Methotrexate—multiple sclerosis	9.88e-05	0.00109	CcSEcCtD
Canagliflozin—Dermatitis—Methotrexate—multiple sclerosis	9.87e-05	0.00109	CcSEcCtD
Canagliflozin—ALB—Hemostasis—CD58—multiple sclerosis	9.86e-05	0.00205	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—MERTK—multiple sclerosis	9.86e-05	0.00205	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—SELPLG—multiple sclerosis	9.86e-05	0.00205	CbGpPWpGaD
Canagliflozin—ABCC2—Transmembrane transport of small molecules—SLC30A7—multiple sclerosis	9.83e-05	0.00205	CbGpPWpGaD
Canagliflozin—ABCB1—Allograft Rejection—HLA-DQB1—multiple sclerosis	9.75e-05	0.00203	CbGpPWpGaD
Canagliflozin—CYP3A4—Biological oxidations—CYP27B1—multiple sclerosis	9.56e-05	0.00199	CbGpPWpGaD
Canagliflozin—CYP3A4—Biological oxidations—CYP24A1—multiple sclerosis	9.56e-05	0.00199	CbGpPWpGaD
Canagliflozin—CYP3A4—Metapathway biotransformation—CYP27B1—multiple sclerosis	9.43e-05	0.00197	CbGpPWpGaD
Canagliflozin—CYP3A4—Metapathway biotransformation—CYP24A1—multiple sclerosis	9.43e-05	0.00197	CbGpPWpGaD
Canagliflozin—ABCB1—Allograft Rejection—CD86—multiple sclerosis	9.39e-05	0.00196	CbGpPWpGaD
Canagliflozin—ALB—Folate Metabolism—ICAM1—multiple sclerosis	9.38e-05	0.00195	CbGpPWpGaD
Canagliflozin—Nausea—Methotrexate—multiple sclerosis	9.31e-05	0.00103	CcSEcCtD
Canagliflozin—ABCB1—Allograft Rejection—CD40LG—multiple sclerosis	9.21e-05	0.00192	CbGpPWpGaD
Canagliflozin—ABCB1—Allograft Rejection—IL10—multiple sclerosis	9.21e-05	0.00192	CbGpPWpGaD
Canagliflozin—ABCB1—Allograft Rejection—IL4—multiple sclerosis	8.96e-05	0.00187	CbGpPWpGaD
Canagliflozin—SLC5A2—Transmembrane transport of small molecules—ALB—multiple sclerosis	8.87e-05	0.00185	CbGpPWpGaD
Canagliflozin—SLC5A1—Transmembrane transport of small molecules—ALB—multiple sclerosis	8.87e-05	0.00185	CbGpPWpGaD
Canagliflozin—SLC5A1—Metabolism—BCHE—multiple sclerosis	8.82e-05	0.00184	CbGpPWpGaD
Canagliflozin—SLC5A2—Metabolism—BCHE—multiple sclerosis	8.82e-05	0.00184	CbGpPWpGaD
Canagliflozin—ALB—Vitamin B12 Metabolism—IFNG—multiple sclerosis	8.77e-05	0.00183	CbGpPWpGaD
Canagliflozin—ABCB1—Allograft Rejection—HLA-B—multiple sclerosis	8.76e-05	0.00182	CbGpPWpGaD
Canagliflozin—ALB—Folate Metabolism—CCL2—multiple sclerosis	8.39e-05	0.00175	CbGpPWpGaD
Canagliflozin—ABCB1—Allograft Rejection—FAS—multiple sclerosis	8.25e-05	0.00172	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—SRM—multiple sclerosis	8.21e-05	0.00171	CbGpPWpGaD
Canagliflozin—ABCB1—Allograft Rejection—IL2RA—multiple sclerosis	8.21e-05	0.00171	CbGpPWpGaD
Canagliflozin—ABCB1—Allograft Rejection—HLA-A—multiple sclerosis	8.11e-05	0.00169	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—CD86—multiple sclerosis	7.85e-05	0.00164	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—CD86—multiple sclerosis	7.85e-05	0.00164	CbGpPWpGaD
Canagliflozin—ALB—Vitamin B12 Metabolism—IL1B—multiple sclerosis	7.82e-05	0.00163	CbGpPWpGaD
Canagliflozin—ABCC2—Transmembrane transport of small molecules—AQP4—multiple sclerosis	7.77e-05	0.00162	CbGpPWpGaD
Canagliflozin—UGT1A9—Biological oxidations—POMC—multiple sclerosis	7.61e-05	0.00159	CbGpPWpGaD
Canagliflozin—ALB—Selenium Micronutrient Network—ICAM1—multiple sclerosis	7.45e-05	0.00155	CbGpPWpGaD
Canagliflozin—ABCB1—Allograft Rejection—HLA-DRB1—multiple sclerosis	7.41e-05	0.00154	CbGpPWpGaD
Canagliflozin—ALB—SLC-mediated transmembrane transport—SLC11A1—multiple sclerosis	7.25e-05	0.00151	CbGpPWpGaD
Canagliflozin—ALB—Folate Metabolism—IFNG—multiple sclerosis	7.13e-05	0.00149	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—CCR5—multiple sclerosis	6.96e-05	0.00145	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—CCR5—multiple sclerosis	6.96e-05	0.00145	CbGpPWpGaD
Canagliflozin—ALB—Transmembrane transport of small molecules—SLC15A2—multiple sclerosis	6.96e-05	0.00145	CbGpPWpGaD
Canagliflozin—ABCC2—Transmembrane transport of small molecules—SLC11A1—multiple sclerosis	6.87e-05	0.00143	CbGpPWpGaD
Canagliflozin—ABCB1—Allograft Rejection—CD80—multiple sclerosis	6.85e-05	0.00143	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—BCHE—multiple sclerosis	6.81e-05	0.00142	CbGpPWpGaD
Canagliflozin—ALB—Metabolism of lipids and lipoproteins—CYP27B1—multiple sclerosis	6.8e-05	0.00142	CbGpPWpGaD
Canagliflozin—ALB—Metabolism of lipids and lipoproteins—CYP24A1—multiple sclerosis	6.8e-05	0.00142	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—HLA-A—multiple sclerosis	6.78e-05	0.00141	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—HLA-A—multiple sclerosis	6.78e-05	0.00141	CbGpPWpGaD
Canagliflozin—ALB—Selenium Micronutrient Network—CCL2—multiple sclerosis	6.67e-05	0.00139	CbGpPWpGaD
Canagliflozin—ALB—Folate Metabolism—IL1B—multiple sclerosis	6.36e-05	0.00133	CbGpPWpGaD
Canagliflozin—ALB—Folate Metabolism—IL2—multiple sclerosis	6.34e-05	0.00132	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—APOE—multiple sclerosis	6.33e-05	0.00132	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—APOE—multiple sclerosis	6.33e-05	0.00132	CbGpPWpGaD
Canagliflozin—ABCB1—Transmembrane transport of small molecules—SLC15A2—multiple sclerosis	6.1e-05	0.00127	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—PLEK—multiple sclerosis	6.09e-05	0.00127	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—TNFRSF1A—multiple sclerosis	5.93e-05	0.00124	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—CYP24A1—multiple sclerosis	5.79e-05	0.00121	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—CYP27B1—multiple sclerosis	5.79e-05	0.00121	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—CD80—multiple sclerosis	5.73e-05	0.00119	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—CD80—multiple sclerosis	5.73e-05	0.00119	CbGpPWpGaD
Canagliflozin—ALB—Vitamin B12 Metabolism—TNF—multiple sclerosis	5.68e-05	0.00118	CbGpPWpGaD
Canagliflozin—ALB—Selenium Micronutrient Network—IFNG—multiple sclerosis	5.67e-05	0.00118	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	5.66e-05	0.00118	CbGpPWpGaD
Canagliflozin—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—multiple sclerosis	5.51e-05	0.00115	CbGpPWpGaD
Canagliflozin—ABCB1—Allograft Rejection—IFNG—multiple sclerosis	5.41e-05	0.00113	CbGpPWpGaD
Canagliflozin—SLC5A1—Metabolism—APOE—multiple sclerosis	5.3e-05	0.0011	CbGpPWpGaD
Canagliflozin—SLC5A2—Metabolism—APOE—multiple sclerosis	5.3e-05	0.0011	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—GPC5—multiple sclerosis	5.29e-05	0.0011	CbGpPWpGaD
Canagliflozin—ALB—Transmembrane transport of small molecules—SLC30A7—multiple sclerosis	5.27e-05	0.0011	CbGpPWpGaD
Canagliflozin—ALB—Selenium Micronutrient Network—IL1B—multiple sclerosis	5.06e-05	0.00105	CbGpPWpGaD
Canagliflozin—UGT1A9—NRF2 pathway—TGFB1—multiple sclerosis	5e-05	0.00104	CbGpPWpGaD
Canagliflozin—CYP3A4—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	5e-05	0.00104	CbGpPWpGaD
Canagliflozin—ABCC2—NRF2 pathway—TGFB1—multiple sclerosis	4.88e-05	0.00102	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—TYK2—multiple sclerosis	4.83e-05	0.00101	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—TYK2—multiple sclerosis	4.83e-05	0.00101	CbGpPWpGaD
Canagliflozin—ABCB1—Allograft Rejection—IL1B—multiple sclerosis	4.83e-05	0.00101	CbGpPWpGaD
Canagliflozin—ABCB1—Allograft Rejection—IL2—multiple sclerosis	4.81e-05	0.001	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—BDNF—multiple sclerosis	4.76e-05	0.000992	CbGpPWpGaD
Canagliflozin—ABCB1—Transmembrane transport of small molecules—SLC30A7—multiple sclerosis	4.62e-05	0.000963	CbGpPWpGaD
Canagliflozin—ALB—Folate Metabolism—TNF—multiple sclerosis	4.62e-05	0.000962	CbGpPWpGaD
Canagliflozin—ALB—Vitamin B12 Metabolism—IL6—multiple sclerosis	4.58e-05	0.000954	CbGpPWpGaD
Canagliflozin—SLC5A2—Metabolism—POMC—multiple sclerosis	4.56e-05	0.000949	CbGpPWpGaD
Canagliflozin—SLC5A1—Metabolism—POMC—multiple sclerosis	4.56e-05	0.000949	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—RRM1—multiple sclerosis	4.39e-05	0.000914	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—CD4—multiple sclerosis	4.37e-05	0.000911	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—CD4—multiple sclerosis	4.37e-05	0.000911	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—SRM—multiple sclerosis	4.3e-05	0.000896	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—SELE—multiple sclerosis	4.29e-05	0.000894	CbGpPWpGaD
Canagliflozin—ALB—Platelet degranulation—TGFB1—multiple sclerosis	4.24e-05	0.000883	CbGpPWpGaD
Canagliflozin—ALB—Transmembrane transport of small molecules—AQP4—multiple sclerosis	4.17e-05	0.000869	CbGpPWpGaD
Canagliflozin—SLC5A1—Metabolism—ALB—multiple sclerosis	4.15e-05	0.000865	CbGpPWpGaD
Canagliflozin—SLC5A2—Metabolism—ALB—multiple sclerosis	4.15e-05	0.000865	CbGpPWpGaD
Canagliflozin—ALB—Platelet activation, signaling and aggregation—IL2RA—multiple sclerosis	4.11e-05	0.000857	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—APOE—multiple sclerosis	4.09e-05	0.000853	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—FAS—multiple sclerosis	4.07e-05	0.000849	CbGpPWpGaD
Canagliflozin—CYP3A4—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	4.05e-05	0.000844	CbGpPWpGaD
Canagliflozin—ALB—Response to elevated platelet cytosolic Ca2+—TGFB1—multiple sclerosis	4.04e-05	0.000842	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—SRM—multiple sclerosis	3.77e-05	0.000785	CbGpPWpGaD
Canagliflozin—ABCB1—Allograft Rejection—TGFB1—multiple sclerosis	3.75e-05	0.000782	CbGpPWpGaD
Canagliflozin—ALB—Folate Metabolism—IL6—multiple sclerosis	3.73e-05	0.000776	CbGpPWpGaD
Canagliflozin—ALB—Transmembrane transport of small molecules—SLC11A1—multiple sclerosis	3.68e-05	0.000768	CbGpPWpGaD
Canagliflozin—ALB—Selenium Micronutrient Network—TNF—multiple sclerosis	3.67e-05	0.000764	CbGpPWpGaD
Canagliflozin—ABCB1—Transmembrane transport of small molecules—AQP4—multiple sclerosis	3.65e-05	0.000761	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—POMC—multiple sclerosis	3.52e-05	0.000733	CbGpPWpGaD
Canagliflozin—ABCB1—Allograft Rejection—TNF—multiple sclerosis	3.5e-05	0.00073	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	3.4e-05	0.000709	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—STAT3—multiple sclerosis	3.38e-05	0.000705	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—STAT3—multiple sclerosis	3.38e-05	0.000705	CbGpPWpGaD
Canagliflozin—ABCB1—Transmembrane transport of small molecules—SLC11A1—multiple sclerosis	3.23e-05	0.000673	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—ALB—multiple sclerosis	3.21e-05	0.000668	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—MYC—multiple sclerosis	3.14e-05	0.000655	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—MYC—multiple sclerosis	3.14e-05	0.000655	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—TGFB1—multiple sclerosis	3.14e-05	0.000654	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—TGFB1—multiple sclerosis	3.14e-05	0.000654	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—ITGA4—multiple sclerosis	3.1e-05	0.000647	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—IFNB1—multiple sclerosis	3.08e-05	0.000642	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—MAPK1—multiple sclerosis	3.08e-05	0.000641	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—MAPK1—multiple sclerosis	3.08e-05	0.000641	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—CYP24A1—multiple sclerosis	3.03e-05	0.000631	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—CYP27B1—multiple sclerosis	3.03e-05	0.000631	CbGpPWpGaD
Canagliflozin—ALB—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	2.96e-05	0.000617	CbGpPWpGaD
Canagliflozin—ALB—Selenium Micronutrient Network—IL6—multiple sclerosis	2.96e-05	0.000617	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	2.92e-05	0.000609	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—GPC5—multiple sclerosis	2.77e-05	0.000577	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	2.66e-05	0.000555	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—CYP27B1—multiple sclerosis	2.65e-05	0.000553	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—CYP24A1—multiple sclerosis	2.65e-05	0.000553	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—BCHE—multiple sclerosis	2.52e-05	0.000525	CbGpPWpGaD
Canagliflozin—ABCC2—Transmembrane transport of small molecules—ALB—multiple sclerosis	2.47e-05	0.000515	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—GPC5—multiple sclerosis	2.43e-05	0.000506	CbGpPWpGaD
Canagliflozin—ALB—Platelet activation, signaling and aggregation—IL2—multiple sclerosis	2.41e-05	0.000502	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—IL6—multiple sclerosis	2.36e-05	0.000492	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—IL6—multiple sclerosis	2.36e-05	0.000492	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—SRM—multiple sclerosis	2.32e-05	0.000484	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—RRM1—multiple sclerosis	2.3e-05	0.000478	CbGpPWpGaD
Canagliflozin—CYP3A4—Biological oxidations—POMC—multiple sclerosis	2.15e-05	0.000448	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—IL2RA—multiple sclerosis	2.12e-05	0.000442	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—RRM1—multiple sclerosis	2.01e-05	0.000419	CbGpPWpGaD
Canagliflozin—ALB—Platelet activation, signaling and aggregation—TGFB1—multiple sclerosis	1.88e-05	0.000392	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—multiple sclerosis	1.86e-05	0.000387	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—multiple sclerosis	1.85e-05	0.000386	CbGpPWpGaD
Canagliflozin—ALB—Platelet activation, signaling and aggregation—MAPK1—multiple sclerosis	1.84e-05	0.000384	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK1—multiple sclerosis	1.82e-05	0.000378	CbGpPWpGaD
Canagliflozin—ALB—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	1.78e-05	0.000371	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—multiple sclerosis	1.73e-05	0.00036	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—CYP27B1—multiple sclerosis	1.64e-05	0.000341	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—CYP24A1—multiple sclerosis	1.64e-05	0.000341	CbGpPWpGaD
Canagliflozin—ALB—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	1.53e-05	0.000319	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—APOE—multiple sclerosis	1.52e-05	0.000316	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—GPC5—multiple sclerosis	1.5e-05	0.000312	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—BCHE—multiple sclerosis	1.32e-05	0.000275	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—POMC—multiple sclerosis	1.3e-05	0.000271	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—IL2—multiple sclerosis	1.24e-05	0.000259	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—RRM1—multiple sclerosis	1.24e-05	0.000258	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—ALB—multiple sclerosis	1.19e-05	0.000247	CbGpPWpGaD
Canagliflozin—ABCB1—Transmembrane transport of small molecules—ALB—multiple sclerosis	1.16e-05	0.000242	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—BCHE—multiple sclerosis	1.16e-05	0.000241	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—TGFB1—multiple sclerosis	9.69e-06	0.000202	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—MAPK1—multiple sclerosis	9.51e-06	0.000198	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—APOE—multiple sclerosis	7.93e-06	0.000165	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—BCHE—multiple sclerosis	7.12e-06	0.000148	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—APOE—multiple sclerosis	6.95e-06	0.000145	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—POMC—multiple sclerosis	6.82e-06	0.000142	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—POMC—multiple sclerosis	5.97e-06	0.000124	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—ALB—multiple sclerosis	5.44e-06	0.000113	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—APOE—multiple sclerosis	4.28e-06	8.92e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—POMC—multiple sclerosis	3.68e-06	7.67e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—ALB—multiple sclerosis	3.35e-06	6.99e-05	CbGpPWpGaD
